

Andrew H Briggs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2766940/publications.pdf>

Version: 2024-02-01

370
papers

29,433
citations

6592

79
h-index

6454

157
g-index

386
all docs

386
docs citations

386
times ranked

32353
citing authors

#	ARTICLE	IF	CITATIONS
1	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)â€™Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 2013, 16, 231-250.	0.1	1,657
2	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ, The, 2013, 346, f1049-f1049.	3.0	1,082
3	Cost-effectiveness acceptability curvesâ€™ facts, fallacies and frequently asked questions. Health Economics (United Kingdom), 2004, 13, 405-415.	0.8	754
4	An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics, 1998, 13, 397-409.	1.7	713
5	Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. , 1997, 6, 327-340.		705
6	Handling Uncertainty in Cost-Effectiveness Models. Pharmacoeconomics, 2000, 17, 479-500.	1.7	659
7	Review of statistical methods for analysing healthcare resources and costs. Health Economics (United Kingdom), 2011, 20, 897-916.	0.8	574
8	Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. Value in Health, 2005, 8, 521-533.	0.1	567
9	Model Parameter Estimation and Uncertainty Analysis. Medical Decision Making, 2012, 32, 722-732.	1.2	564
10	Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research. PLoS Medicine, 2013, 10, e1001380.	3.9	561
11	Oral versus Intravenous Antibiotics for Bone and Joint Infection. New England Journal of Medicine, 2019, 380, 425-436.	13.9	548
12	Cost-Effectiveness Analysis Alongside Clinical Trials IIâ€™An ISPOR Good Research Practices Task Force Report. Value in Health, 2015, 18, 161-172.	0.1	539
13	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Value in Health, 2013, 16, e1-e5.	0.1	513
14	Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Economics (United Kingdom), 1994, 3, 95-104.	0.8	487
15	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Journal of Allergy and Clinical Immunology, 2012, 130, 1049-1062.	1.5	486
16	Modeling Good Research Practicesâ€™Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value in Health, 2012, 15, 796-803.	0.1	481
17	Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value in Health, 2012, 15, 835-842.	0.1	478
18	Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes. BMJ, The, 2013, 346, e5595-e5595.	3.0	450

#	ARTICLE	IF	CITATIONS
19	Something old, something new, something borrowed, something blue: a framework for the marriage of health economics and cost-effectiveness analysis. <i>Health Economics (United Kingdom)</i> , 2002, 11, 415-430.	0.8	435
20	Modeling Good Research Practices—Overview. <i>Medical Decision Making</i> , 2012, 32, 667-677.	1.2	389
21	The death of cost-minimization analysis?. <i>Health Economics (United Kingdom)</i> , 2001, 10, 179-184.	0.8	377
22	Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. <i>Health Economics (United Kingdom)</i> , 2005, 14, 339-347.	0.8	368
23	Prognosis research strategy (PROGRESS) 4: Stratified medicine research. <i>BMJ, The</i> , 2013, 346, e5793-e5793.	3.0	367
24	Thinking Outside the Box: Recent Advances in the Analysis and Presentation of Uncertainty in Cost-Effectiveness Studies. <i>Annual Review of Public Health</i> , 2002, 23, 377-401.	7.6	351
25	Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, 7, 723-740.		323
26	Inhaler competence in asthma: Common errors, barriers to use and recommended solutions. <i>Respiratory Medicine</i> , 2013, 107, 37-46.	1.3	289
27	Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. <i>Health Economics (United Kingdom)</i> , 2004, 13, 461-475.	0.8	285
28	CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 117-122.	0.2	281
29	Missing.... presumed at random: cost-analysis of incomplete data. <i>Health Economics (United Kingdom)</i> , 2003, 12, 377-392.	0.8	280
30	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Cost Effectiveness and Resource Allocation</i> , 2013, 11, 6.	0.6	264
31	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Value in Health</i> , 2022, 25, 3-9.	0.1	254
32	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. <i>Value in Health</i> , 2022, 25, 10-31.	0.1	251
33	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. <i>European Heart Journal</i> , 2015, 36, 100-111.	1.0	241
34	Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. <i>Value in Health</i> , 2013, 16, 703-719.	0.1	237
35	Optimal Cost-Effectiveness Decisions: The Role of the Cost-Effectiveness Acceptability Curve (CEAC), the Cost-Effectiveness Acceptability Frontier (CEAF), and the Expected Value of Perfection Information (EVPI). <i>Value in Health</i> , 2008, 11, 886-897.	0.1	227
36	The Distribution of Health Care Costs and Their Statistical Analysis for Economic Evaluation. <i>Journal of Health Services Research and Policy</i> , 1998, 3, 233-245.	0.8	220

#	ARTICLE	IF	CITATIONS
37	A Bayesian approach to stochastic cost-effectiveness analysis. <i>Health Economics (United Kingdom)</i> , 1999, 8, 257-261.	0.8	205
38	Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. <i>Statistical Methods in Medical Research</i> , 2002, 11, 455-468.	0.7	205
39	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. <i>Value in Health</i> , 2016, 19, 921-928.	0.1	203
40	Cardiac Troponin T and Troponin I in the General Population. <i>Circulation</i> , 2019, 139, 2754-2764.	1.6	200
41	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>European Journal of Health Economics</i> , 2013, 14, 367-372.	1.4	191
42	Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease. <i>Medical Decision Making</i> , 2002, 22, 290-308.	1.2	188
43	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BMC Medicine</i> , 2013, 11, 80.	2.3	185
44	Value based pricing for NHS drugs: an opportunity not to be missed?. <i>BMJ: British Medical Journal</i> , 2008, 336, 251-254.	2.4	178
45	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	2.7	160
46	Methods in health service research: Handling uncertainty in economic evaluations of healthcare interventions. <i>BMJ: British Medical Journal</i> , 1999, 319, 635-638.	2.4	155
47	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. <i>Journal of Health Services Research and Policy</i> , 2007, 12, 56-58.	0.8	155
48	Probabilistic Analysis of Cost-Effectiveness Models: Statistical Representation of Parameter Uncertainty. <i>Value in Health</i> , 2005, 8, 1-2.	0.1	154
49	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014, 44, 304-323.	3.1	154
50	Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. <i>BMJ: British Medical Journal</i> , 2011, 343, d4044-d4044.	2.4	149
51	Questionnaire to Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report. <i>Value in Health</i> , 2014, 17, 174-182.	0.1	147
52	Probabilistic Sensitivity Analysis for Decision Trees with Multiple Branches: Use of the Dirichlet Distribution in a Bayesian Framework. <i>Medical Decision Making</i> , 2003, 23, 341-350.	1.2	145
53	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BMJ, The</i> , 2022, 376, e067975.	3.0	141
54	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology, The</i> , 2018, 19, 562-578.	5.1	133

#	ARTICLE	IF	CITATIONS
55	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A <sc>EUFOREA</sc> – <sc>ARIA</sc> – <sc>EPOS</sc> – <sc>AIRWAYS ICP</sc> statement. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1297-1305.	2.7	130
56	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	1.5	128
57	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Pharmacoeconomics, 2013, 31, 361-367.	1.7	124
58	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	1.4	121
59	Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care. Lancet, The, 2000, 356, 1965-1969.	6.3	120
60	The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. Value in Health, 2008, 11, 527-538.	0.1	118
61	Development of an Economic Model to Assess the Cost Effectiveness of Treatment Interventions for Chronic Obstructive Pulmonary Disease. Pharmacoeconomics, 2005, 23, 619-637.	1.7	117
62	Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. , 1999, 18, 3245-3262.		116
63	Improving the Transparency of Prognosis Research: The Role of Reporting, Data Sharing, Registration, and Protocols. PLoS Medicine, 2014, 11, e1001671.	3.9	112
64	Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals. Lancet, The, 2005, 365, 1779-1785.	6.3	106
65	Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling. Medical Decision Making, 2017, 37, 427-439.	1.2	105
66	Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. Value in Health, 2016, 19, 704-719.	0.1	101
67	Comparison between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. Clinical Chemistry, 2018, 64, 1607-1616.	1.5	101
68	Sensitivity analysis in economic evaluation: A review of published studies. Health Economics (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	99
69	Outcome Measurement in Economic Evaluations of Public Health Interventions: a Role for the Capability Approach?. International Journal of Environmental Research and Public Health, 2010, 7, 2274-2289.	1.2	98
70	Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Economics (United Kingdom), 2001, 10, 675-680.	0.8	96
71	Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health and Quality of Life Outcomes, 2008, 6, 105.	1.0	96
72	Close Contact Casting vs Surgery for Initial Treatment of Unstable Ankle Fractures in Older Adults. JAMA - Journal of the American Medical Association, 2016, 316, 1455.	3.8	94

#	ARTICLE	IF	CITATIONS
73	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. <i>American Heart Journal</i> , 2016, 172, 160-169.	1.2	93
74	Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. <i>Health Economics (United Kingdom)</i> , 2005, 14, 471-485.	0.8	92
75	Meta-analysis of mixed treatment comparisons at multiple follow-up times. <i>Statistics in Medicine</i> , 2007, 26, 3681-3699.	0.8	92
76	Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. <i>European Journal of Health Economics</i> , 2010, 11, 427-434.	1.4	92
77	Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2001, 1, 25-36.	0.7	89
78	Parametric modelling of cost data: some simulation evidence. <i>Health Economics (United Kingdom)</i> , 2005, 14, 421-428.	0.8	84
79	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 735-750.	2.7	83
80	Development of an Economic Model to Assess the Cost Effectiveness of Asthma Management Strategies. <i>Pharmacoeconomics</i> , 2002, 20, 183-194.	1.7	82
81	Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. <i>American Heart Journal</i> , 2005, 149, 434-443.	1.2	82
82	Predicting EQ-5D Values Using the SGRQ. <i>Value in Health</i> , 2011, 14, 354-360.	0.1	81
83	Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20%536 people. <i>BMJ: British Medical Journal</i> , 2006, 333, 1145.	2.4	80
84	Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. <i>Health Economics (United Kingdom)</i> , 2006, 15, 1-4.	0.8	79
85	Development and Validation of a Prognostic Index for Health Outcomes in Chronic Obstructive Pulmonary Disease. <i>Archives of Internal Medicine</i> , 2008, 168, 71.	4.3	78
86	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e13.	0.2	78
87	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. <i>Cancer Research</i> , 2020, 80, 5427-5434.	0.4	77
88	The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years. <i>Health Technology Assessment</i> , 2016, 20, 1-158.	1.3	73
89	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BMC Medicine</i> , 2022, 20, 23.	2.3	73
90	Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 531-536.	2.7	72

#	ARTICLE	IF	CITATIONS
91	Sex Differences in Incidence, Mortality, and Survival in Individuals With Stroke in Scotland, 1986 to 2005. <i>Stroke</i> , 2009, 40, 1038-1043.	1.0	69
92	“Highest risk” “highest benefit”™ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. <i>European Heart Journal</i> , 2018, 39, 2546-2550.	1.0	69
93	Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference Elicitation in TRIAls) review. <i>Health Technology Assessment</i> , 2014, 18, v-vi, 1-175.	1.3	68
94	Power and Sample Size Calculations for Stochastic Cost-Effectiveness Analysis. <i>Medical Decision Making</i> , 1998, 18, S81-S92.	1.2	67
95	How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 765-774.	2.7	67
96	Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1548.	3.8	67
97	Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. <i>Diabetologia</i> , 2013, 56, 1716-1725.	2.9	64
98	Count the cost of disability caused by COVID-19. <i>Nature</i> , 2021, 593, 502-505.	13.7	64
99	Expanding access to HAART: a cost-effective approach for treating and preventing HIV. <i>Aids</i> , 2010, 24, 1929-1935.	1.0	63
100	Operationalising the capability approach as an outcome measure in public health: The development of the OCAP-18. <i>Social Science and Medicine</i> , 2015, 142, 68-81.	1.8	63
101	Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. <i>Pharmacoeconomics</i> , 2018, 36, 1421-1426.	1.7	63
102	Statistical approaches to handling uncertainty in health economic evaluation. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 551-561.	0.8	61
103	Are financial incentives cost-effective to support smoking cessation during pregnancy?. <i>Addiction</i> , 2016, 111, 360-370.	1.7	61
104	Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. <i>European Respiratory Journal</i> , 2010, 35, 532-539.	3.1	59
105	Cost-effectiveness Analysis in <tt>R</tt> Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. <i>Medical Decision Making</i> , 2017, 37, 340-352.	1.2	58
106	Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations. <i>Pharmacoeconomics</i> , 2019, 37, 1129-1138.	1.7	58
107	Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. <i>European Heart Journal</i> , 2006, 27, 796-801.	1.0	57
108	Acute Rejection and Chronic Nephropathy: A Systematic Review of the Literature. <i>Transplantation</i> , 2009, 87, 1330-1339.	0.5	57

#	ARTICLE	IF	CITATIONS
109	Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. <i>Health Economics (United Kingdom)</i> , 2021, 30, 699-707.	0.8	57
110	One-Year Outcomes and a Cost-Effectiveness Analysis for Smokers Accessing Group-Based and Pharmacy-Led Cessation Services. <i>Nicotine and Tobacco Research</i> , 2011, 13, 135-145.	1.4	56
111	A BAYESIAN APPROACH TO STOCHASTIC COST-EFFECTIVENESS ANALYSIS. <i>International Journal of Technology Assessment in Health Care</i> , 2001, 17, 69-82.	0.2	55
112	Acknowledging Patient Heterogeneity in Economic Evaluation. <i>Pharmacoeconomics</i> , 2013, 31, 111-123.	1.7	55
113	How cost-effective is screening for abdominal aortic aneurysms?. <i>Journal of Medical Screening</i> , 2007, 14, 46-52.	1.1	54
114	Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. <i>Heart</i> , 2007, 93, 1081-1086.	1.2	53
115	Cost-Effectiveness of Lifestyle Modification in Diabetic Patients. <i>Diabetes Care</i> , 2009, 32, 1453-1458.	4.3	52
116	Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers. <i>Trials</i> , 2015, 16, 12.	0.7	52
117	Comparison of behavioural activation with guided self-help for treatment of depression in adults with intellectual disabilities: a randomised controlled trial. <i>Lancet Psychiatry</i> , 2017, 4, 909-919.	3.7	52
118	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. <i>European Respiratory Journal</i> , 2016, 47, 1028-1033.	3.1	50
119	Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. <i>Heart</i> , 2018, 104, 1006-1013.	1.2	50
120	Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. <i>European Respiratory Journal</i> , 2020, 57, 2000670.	3.1	50
121	Incorporation of uncertainty in health economic modelling studies. <i>Pharmacoeconomics</i> , 2005, 23, 529-536.	1.7	49
122	Health Technology Assessment in the Cost-Disutility Plane. <i>Medical Decision Making</i> , 2008, 28, 172-181.	1.2	49
123	Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 583.	0.7	48
124	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2297-2308.	1.2	48
125	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016, 6, 29.	1.4	47
126	Treatment of Early-Stage Breast Cancer in the Elderly. <i>Medical Decision Making</i> , 1998, 18, 213-219.	1.2	46

#	ARTICLE	IF	CITATIONS
127	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	2.7	46
128	The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. <i>Medical Journal of Australia</i> , 1994, 160, 268-272.	0.8	46
129	The Use of Probabilistic Decision Models in Technology Assessment. <i>Applied Health Economics and Health Policy</i> , 2004, 3, 79-89.	1.0	45
130	Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. <i>Journal of Medical Screening</i> , 2015, 22, 158-164.	1.1	45
131	Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. , 2000, 9, 191-198.		43
132	The progressivity of health-care financing in Kenya. <i>Health Policy and Planning</i> , 2014, 29, 912-920.	1.0	43
133	Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT [®] -Lung Test (ECLS): study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2017, 17, 187.	1.1	43
134	Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. <i>Addiction</i> , 2009, 104, 317-325.	1.7	41
135	International Comparison of Comparative Effectiveness Research in Five Jurisdictions. <i>Pharmacoeconomics</i> , 2010, 28, 813-830.	1.7	41
136	Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). <i>PLoS ONE</i> , 2013, 8, e72642.	1.1	41
137	Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. <i>Value in Health</i> , 2014, 17, 525-536.	0.1	41
138	Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. <i>British Journal of Cancer</i> , 2010, 103, 776-786.	2.9	39
139	The Ends Justify the Mean: Outcome Measures for Estimating the Value of New Cancer Therapies. <i>Health Outcomes Research in Medicine</i> , 2012, 3, e25-e36.	0.6	39
140	The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. <i>Diabetologia</i> , 2012, 55, 2356-2360.	2.9	39
141	SPOILT FOR CHOICE: IMPLICATIONS OF USING ALTERNATIVE METHODS OF COSTING HOSPITAL EPISODE STATISTICS. <i>Health Economics (United Kingdom)</i> , 2012, 21, 1201-1216.	0.8	39
142	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Pharmacoeconomics</i> , 2022, 40, 601-609.	1.7	39
143	Prevention of mother-to-child transmission of HIV-1 infection. <i>Aids</i> , 1998, 12, 1381-1388.	1.0	38
144	Population ageing and healthcare expenditure projections: new evidence from a time to death approach. <i>European Journal of Health Economics</i> , 2014, 15, 885-896.	1.4	38

#	ARTICLE	IF	CITATIONS
145	How methodological frameworks are being developed: evidence from a scoping review. <i>BMC Medical Research Methodology</i> , 2020, 20, 173.	1.4	38
146	Cost-effectiveness of β -blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. <i>American Heart Journal</i> , 2001, 142, 537-543.	1.2	37
147	Uterine artery embolisation or hysterectomy for the treatment of symptomatic uterine fibroids: a cost-utility analysis of the HOPEFUL study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2007, 114, 1352-1362.	1.1	37
148	Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1301-1305.	0.9	37
149	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 765-770.	1.1	36
150	The "Hazards" of Extrapolating Survival Curves. <i>Medical Decision Making</i> , 2013, 33, 369-380.	1.2	36
151	Access with Evidence Development in the UK. <i>Pharmacoeconomics</i> , 2010, 28, 163-170.	1.7	33
152	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1096-1104.	2.3	33
153	Recombinant Erythropoietin for Chemotherapy-Related Anaemia. <i>Pharmacoeconomics</i> , 2007, 25, 223-237.	1.7	32
154	Achieved Levels of HbA1c and Likelihood of Hospital Admission in People With Type 1 Diabetes in the Scottish Population. <i>Diabetes Care</i> , 2011, 34, 1992-1997.	4.3	32
155	Trying to do better than average: a commentary on "statistical inference for cost-effectiveness ratios". <i>Value in Health</i> , 1997, 6, 491-495.		30
156	Estimating the Cost-Effectiveness of Fluticasone Propionate for Treating Chronic Obstructive Pulmonary Disease in the Presence of Missing Data. <i>Value in Health</i> , 2006, 9, 227-235.	0.1	30
157	Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. <i>Diabetologia</i> , 2014, 57, 2513-2520.	2.9	30
158	Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. <i>International Journal of COPD</i> , 2017, Volume 12, 3183-3194.	0.9	30
159	Long-term weight loss trajectories following participation in a randomised controlled trial of a weight management programme for men delivered through professional football clubs: a longitudinal cohort study and economic evaluation. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2018, 15, 60.	2.0	30
160	Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. <i>BMC Medicine</i> , 2010, 8, 23.	2.3	29
161	Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model. <i>Medical Decision Making</i> , 2017, 37, 469-480.	1.2	29
162	A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: Pilot trial outcomes (ADAPT). <i>Schizophrenia Research</i> , 2017, 183, 143-150.	1.1	29

#	ARTICLE	IF	CITATIONS
163	The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. <i>Journal of Health Services Research and Policy</i> , 2007, 12, 11-17G.	0.8	28
164	Model Averaging in the Presence of Structural Uncertainty about Treatment Effects: Influence on Treatment Decision and Expected Value of Information. <i>Value in Health</i> , 2011, 14, 205-218.	0.1	27
165	Methods for Specifying the Target Difference in a Randomised Controlled Trial: The Difference Elicitation in TriAls (DELTA) Systematic Review. <i>PLoS Medicine</i> , 2014, 11, e1001645.	3.9	27
166	The "in Cost-Effectiveness Analyses. A Case Study of Omalizumab Efficacy and Effectiveness for Cost-Effectiveness Analysis Evidence. <i>Annals of the American Thoracic Society</i> , 2014, 11, S105-S111.	1.5	27
167	Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn. <i>Value in Health</i> , 2002, 5, 312-328.	0.1	26
168	Age- and Sex-Specific Trends in Fatal Incidence and Hospitalized Incidence of Stroke in Scotland, 1986 to 2005. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 475-483.	0.9	26
169	A patient-centred approach to estimate total annual healthcare cost by body mass index in the UK Counterweight programme. <i>International Journal of Obesity</i> , 2013, 37, 1135-1139.	1.6	26
170	Type 2 diabetes remission: 2-year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme. <i>Diabetologia</i> , 2020, 63, 2112-2122.	2.9	26
171	Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetologia</i> , 2011, 54, 2000-2008.	2.9	25
172	Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 310.	1.0	25
173	Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study. <i>BMC Neurology</i> , 2011, 11, 38.	0.8	24
174	A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation. <i>Heart</i> , 2015, 101, 201-208.	1.2	24
175	Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. <i>Medical Decision Making</i> , 2017, 37, 453-468.	1.2	24
176	Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support. <i>JMIR Research Protocols</i> , 2020, 9, e15058.	0.5	24
177	Long-term weight loss following a randomised controlled trial of a weight management programme for men delivered through professional football clubs: the Football Fans in Training follow-up study. <i>Public Health Research</i> , 2018, 6, 1-114.	0.5	24
178	Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. <i>European Journal of Health Economics</i> , 2014, 15, 69-82.	1.4	23
179	Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. <i>Health Economics (United Kingdom)</i> , 2016, 25, 933-938.	0.8	23
180	External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. <i>Value in Health</i> , 2017, 20, 397-403.	0.1	23

#	ARTICLE	IF	CITATIONS
181	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. <i>Diabetes Research and Clinical Practice</i> , 2017, 130, 24-33.	1.1	22
182	PATHway I: design and rationale for the investigation of the feasibility, clinical effectiveness and cost-effectiveness of a technology-enabled cardiac rehabilitation platform. <i>BMJ Open</i> , 2017, 7, e016781.	0.8	22
183	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. <i>American Heart Journal</i> , 2018, 201, 86-94.	1.2	22
184	Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 169-172.	5.5	22
185	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Clinical Therapeutics</i> , 2022, 44, 158-168.	1.1	22
186	Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease. <i>Medical Decision Making</i> , 2017, 37, 440-452.	1.2	21
187	The Costs and Benefits of Primary Total Hip Replacement: How Likely Are New Prostheses To Be Cost-effective?. <i>International Journal of Technology Assessment in Health Care</i> , 1998, 14, 743-761.	0.2	20
188	Treatment Costs in Canada of Health Conditions Resulting From Chronic Hepatitis B Infection. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, S179-S186.	1.1	20
189	TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 12-19.	0.2	20
190	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 267.	0.7	20
191	Communicating the Parameter Uncertainty in the IQWiG Efficiency Frontier to Decision Makers. <i>Health Economics (United Kingdom)</i> , 2015, 24, 481-490.	0.8	20
192	Enhancing Health Through Access to Nature: How Effective are Interventions in Woodlands in Deprived Urban Communities? A Quasi-experimental Study in Scotland, UK. <i>Sustainability</i> , 2019, 11, 3317.	1.6	20
193	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-88.	1.3	20
194	Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective. <i>Pharmacoeconomics</i> , 2021, 39, 1343-1354.	1.7	20
195	Pharmacoeconomics and Pharmacoepidemiology. <i>Pharmacoeconomics</i> , 2006, 24, 1079-1086.	1.7	19
196	A Systematic Review of Continuous Performance Task Research in Children Prenatally Exposed to Alcohol. <i>Alcohol and Alcoholism</i> , 2010, 45, 30-38.	0.9	19
197	Mobile Phone Use for Contacting Emergency Services in Life-threatening Circumstances. <i>Journal of Emergency Medicine</i> , 2012, 42, 291-298.e3.	0.3	19
198	The Cessation in Pregnancy Incentives Trial (CPIT): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 113.	0.7	19

#	ARTICLE	IF	CITATIONS
199	Analyzing Health-Related Quality of Life in the EVOLVE Trial. <i>Medical Decision Making</i> , 2016, 36, 965-972.	1.2	19
200	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1332-1338.	2.9	19
201	A MODEL FOR ANALYZING THE COST OF MAIN CLINICAL EVENTS AFTER CARDIAC TRANSPLANTATION1. <i>Transplantation</i> , 1996, 62, 615-621.	0.5	19
202	Health impacts of environmental and social interventions designed to increase deprived communities' access to urban woodlands: a mixed-methods study. <i>Public Health Research</i> , 2019, 7, 1-172.	0.5	19
203	Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting β_2 -agonists in a health maintenance organization. <i>Respiratory Medicine</i> , 2005, 99, 1534-1545.	1.3	18
204	Cost-Effectiveness Acceptability Curves in the Dock. <i>Medical Decision Making</i> , 2007, 27, 93-95.	1.2	18
205	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Journal of Medical Economics</i> , 2013, 16, 713-719.	1.0	18
206	Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight+ weight management programme within a primary care randomized controlled trial. <i>Diabetic Medicine</i> , 2019, 36, 1003-1012.	1.2	18
207	Power and sample size for cost-effectiveness analysis: fFN neonatal screening. <i>Contemporary Clinical Trials</i> , 2011, 32, 893-901.	0.8	17
208	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. <i>Clinical Therapeutics</i> , 2013, 35, 356-363.	1.1	17
209	Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1754-1759.	2.9	17
210	Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. <i>Quality of Life Research</i> , 2010, 19, 323-331.	1.5	16
211	An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. <i>European Journal of Heart Failure</i> , 2010, 12, 66-74.	2.9	16
212	ARE VALUE OF INFORMATION METHODS READY FOR PRIME TIME? AN APPLICATION TO ALTERNATIVE TREATMENT STRATEGIES FOR NSTEMI PATIENTS. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 435-442.	0.2	16
213	Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. <i>Value in Health</i> , 2015, 18, 1079-1087.	0.1	16
214	Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy. <i>Value in Health</i> , 2016, 19, 374-382.	0.1	16
215	Bayesian Solutions for Handling Uncertainty in Survival Extrapolation. <i>Medical Decision Making</i> , 2017, 37, 367-376.	1.2	16
216	Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. <i>Cancers</i> , 2020, 12, 3246.	1.7	16

#	ARTICLE	IF	CITATIONS
217	Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. <i>Health Technology Assessment</i> , 2022, 26, 1-174.	1.3	16
218	How effective is the Forestry Commission Scotland's woodland improvement programme "Woods In and Around Towns" (WIAT) at improving psychological well-being in deprived urban communities? A quasi-experimental study. <i>BMJ Open</i> , 2013, 3, e003648.	0.8	15
219	Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators. <i>Social Science and Medicine</i> , 2016, 169, 141-148.	1.8	15
220	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. <i>Medical Decision Making</i> , 2020, 40, 460-473.	1.2	15
221	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , 0, 4, 108.	0.9	15
222	How Do Diabetes Models Measure Up? A Review of Diabetes Economic Models and ADA Guidelines. <i>Journal of Health Economics and Outcomes Research</i> , 2015, 3, 132-152.	0.6	15
223	Pharmacoeconomics in COPD: lessons for the future. <i>International Journal of COPD</i> , 2008, 3, 71-88.	0.9	15
224	Transportability of Comparative Effectiveness and Cost-Effectiveness between Countries. <i>Value in Health</i> , 2010, 13, S22-S25.	0.1	14
225	Time trends in 30 day case-fatality following hospitalisation for asthma in adults in Scotland: A retrospective cohort study from 1981 to 2009. <i>Respiratory Medicine</i> , 2013, 107, 1172-1177.	1.3	14
226	Ankle Injury Management (AIM): design of a pragmatic multi-centre equivalence randomised controlled trial comparing Close Contact Casting (CCC) to Open surgical Reduction and Internal Fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60 years. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 79.	0.8	14
227	Projecting Long-Term Graft and Patient Survival after Transplantation. <i>Value in Health</i> , 2014, 17, 254-260.	0.1	14
228	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 19.	0.6	14
229	BEAT-IT: Comparing a behavioural activation treatment for depression in adults with intellectual disabilities with an attention control: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 595.	0.7	14
230	Cost-Effectiveness Uncertainty Analysis Methods. <i>Medical Decision Making</i> , 2015, 35, 596-607.	1.2	14
231	Using an iterative approach to economic evaluation in the drug development process. <i>Drug Development Research</i> , 2010, 71, 470-477.	1.4	13
232	The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia. <i>Lancet Psychiatry</i> , 2022, 9, 477-486.	3.7	13
233	Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. <i>Value in Health</i> , 2011, 14, 15-23.	0.1	12
234	Hospital Expenditure at the End-of-Life: What Are the Impacts of Health Status and Health Risks?. <i>PLoS ONE</i> , 2015, 10, e0119035.	1.1	12

#	ARTICLE	IF	CITATIONS
235	Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost. <i>Annals of Surgical Oncology</i> , 2020, 27, 5248-5256.	0.7	12
236	Handling Uncertainty in Economic Evaluation. , 0, , 314-337.		12
237	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 213.	1.0	12
238	The Design and Analysis of Stochastic Cost-Effectiveness Studies for the Evaluation of Health Care Interventions. <i>Drug Information Journal</i> , 2001, 35, 1455-1468.	0.5	11
239	Fractional flow reserve versus angiography in guiding management to optimize outcomes in non-â€“ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial. <i>American Heart Journal</i> , 2013, 166, 662-668.e3.	1.2	11
240	Development and validation of a cost-â€“utility model for Type-1 diabetes mellitus. <i>Diabetic Medicine</i> , 2015, 32, 1023-1035.	1.2	11
241	Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. <i>Value in Health</i> , 2016, 19, 800-810.	0.1	11
242	The feasibility of a randomised controlled trial to compare the cost-effectiveness of palliative cardiology or usual care in people with advanced heart failure: Two exploratory prospective cohorts. <i>Palliative Medicine</i> , 2018, 32, 1133-1141.	1.3	11
243	Stratified medicine using invasive coronary function testing in angina: A cost-effectiveness analysis of the British Heart Foundation CorMicA trial. <i>International Journal of Cardiology</i> , 2021, 337, 44-51.	0.8	11
244	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. <i>Health Policy OPEN</i> , 2022, 3, 100063.	0.5	11
245	Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2022, 145, 1312-1323.	1.6	11
246	Perioperative and long-term outcomes following aortic valve replacement: a population cohort study of 4124 consecutive patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 40, 1508-14.	0.6	10
247	Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. <i>BMJ Open</i> , 2015, 5, e007925.	0.8	10
248	A View from the Bridge: Health Economic Evaluation â€“ A Value-â€“Based Framework?. <i>Health Economics (United Kingdom)</i> , 2016, 25, 1499-1502.	0.8	10
249	A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia. <i>Advances in Therapy</i> , 2016, 33, 1814-1830.	1.3	10
250	A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. <i>Pharmacoeconomics</i> , 2018, 36, 603-612.	1.7	10
251	Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 715-721.	0.7	10
252	Evaluation of Health in Pregnancy grants in Scotland: a natural experiment using routine data. <i>Public Health Research</i> , 2017, 5, 1-278.	0.5	10

#	ARTICLE	IF	CITATIONS
253	Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?. <i>Trials</i> , 2011, 12, .	0.7	9
254	Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 705-713.	0.7	9
255	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , 2019, 4, 108.	0.9	9
256	Behavioural activation versus guided self-help for depression in adults with learning disabilities: the BeatIt RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-130.	1.3	9
257	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Journal of Medical Economics</i> , 2022, 25, 1-7.	1.0	9
258	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>European Journal of Health Economics</i> , 2022, 23, 1309-1317.	1.4	9
259	Use of methods for specifying the target difference in randomised controlled trial sample size calculations: Two surveys of trialistsâ€™ practice. <i>Clinical Trials</i> , 2014, 11, 300-308.	0.7	8
260	Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2016, Volume 8, 323-333.	0.7	8
261	Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 547-554e1.	0.2	8
262	The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data. <i>Journal of Patient-Reported Outcomes</i> , 2021, 5, 6.	0.9	8
263	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. <i>Pharmacoeconomics</i> , 2021, 39, 1201-1208.	1.7	8
264	Comparison of Lost Productivity Due to Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal Hemoglobinuria in France, Germany, Italy, Russia, Spain, the United Kingdom, and the United States. <i>Blood</i> , 2019, 134, 4803-4803.	0.6	8
265	The Scottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011. <i>PLoS ONE</i> , 2016, 11, e0162980.	1.1	8
266	Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration. <i>Pharmacoeconomics</i> , 2015, 33, 535-536.	1.7	7
267	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. <i>American Heart Journal</i> , 2015, 170, 951-960.	1.2	7
268	Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma. <i>BioDrugs</i> , 2016, 30, 307-319.	2.2	7
269	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABC-ACS). <i>Open Heart</i> , 2016, 3, e000371.	0.9	7
270	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. <i>Journal of Medical Economics</i> , 2017, 20, 8-18.	1.0	7

#	ARTICLE	IF	CITATIONS
271	<p>Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 551-565.	0.7	7
272	Artificial neural network metamodel for sensitivity analysis in a total hip replacement health economic model. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 629-640.	0.7	7
273	A different animal? Identifying the features of health technology assessment for developers of medical technologies. International Journal of Technology Assessment in Health Care, 2020, 36, 285-291.	0.2	7
274	Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, 7, 723.		7
275	Commentary: Markov models of medical prognosis. BMJ: British Medical Journal, 1997, 314, 354-354.	2.4	7
276	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. Health Technology Assessment, 2019, 23, 1-146.	1.3	7
277	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Public Health, 2022, 22, 179.	1.2	7
278	Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study. Value in Health, 2022, 25, 1002-1009.	0.1	7
279	Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. BMC Neurology, 2015, 15, 3.	0.8	6
280	A cardiovascular disease policy model: part 2â€”preparing for economic evaluation and to assess health inequalities. Open Heart, 2016, 3, e000140.	0.9	6
281	Editorial. Health Economics (United Kingdom), 2016, 25, 6-8.	0.8	6
282	EQ-5D-5L: Smaller steps but a major step change?. Health Economics (United Kingdom), 2018, 27, 4-6.	0.8	6
283	Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value. Health Affairs, 2018, 37, 1298-1305.	2.5	6
284	Comparison of health state utility estimates from instrument-based and vignette-based methods: a case study in kidney disease. BMC Research Notes, 2019, 12, 385.	0.6	6
285	The impact of patient education on consideration of enrollment in clinical trials. Journal of Community and Supportive Oncology, 2018, 16, e81-e88.	0.1	6
286	A Bayesian Approach to Aid in Formulary Decision Making: Incorporating Institution-Specific Cost-Effectiveness Data with Clinical Trial Results. Medical Decision Making, 2003, 23, 252-264.	1.2	5
287	New methods of analysing cost effectiveness. BMJ: British Medical Journal, 2007, 335, 622-623.	2.4	5
288	Comparative Effectiveness Research Through the Looking Glass. Medical Decision Making, 2009, 29, NP6-NP8.	1.2	5

#	ARTICLE	IF	CITATIONS
289	SurgiCal Obesity Treatment Study (SCOTS): protocol for a national prospective cohort study of patients undergoing bariatric surgery in Scotland. <i>BMJ Open</i> , 2015, 5, e008106-e008106.	0.8	5
290	Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. <i>Respiratory Medicine</i> , 2018, 145, 130-137.	1.3	5
291	<p>Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 939-951.	0.9	5
292	Using Nominal Group Technique to Identify Key Attributes of Oncology Treatments for a Discrete Choice Experiment. <i>MDM Policy and Practice</i> , 2019, 4, 238146831983792.	0.5	5
293	A toolkit of methods of development-focused health technology assessment. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, .	0.2	5
294	Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3514-3514.	0.8	5
295	Modifying Alcohol Consumption to Reduce Obesity (MACRO): development and feasibility trial of a complex community-based intervention for men. <i>Health Technology Assessment</i> , 2017, 21, 1-150.	1.3	5
296	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BMC Health Services Research</i> , 2022, 22, 114.	0.9	5
297	Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 555-565.	0.5	5
298	A glossary of economic terms. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 563-565.	0.8	4
299	Nurse led versus lay educators support for those with asthma in primary care: a costing study. <i>BMC Pulmonary Medicine</i> , 2012, 12, 52.	0.8	4
300	Evaluation of Health in Pregnancy grants in Scotland: a protocol for a natural experiment. <i>BMJ Open</i> , 2014, 4, e006547.	0.8	4
301	Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 17.	0.6	4
302	Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: A UK perspective. <i>Respiratory Medicine: X</i> , 2019, 1, 100008.	1.4	4
303	A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. <i>Journal of Medical Economics</i> , 2020, 23, 64-69.	1.0	4
304	Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. <i>European Journal of Health Economics</i> , 2020, 21, 1197-1209.	1.4	4
305	Cost-effectiveness of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 18-18.	0.8	4
306	Interferon-Î± in Hepatitis C. <i>Pharmacoeconomics</i> , 1996, 10, 205-209.	1.7	3

#	ARTICLE	IF	CITATIONS
307	Appropriate Cohorts for Cost-Effectiveness Analysis: To Mix or Not to Mix?. <i>Medical Decision Making</i> , 2010, 30, 424-425.	1.2	3
308	Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting. <i>Oncology and Therapy</i> , 2019, 7, 141-157.	1.0	3
309	Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review. <i>BMJ Open</i> , 2020, 10, e034209.	0.8	3
310	Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin. <i>Pharmacoeconomics</i> , 2021, 39, 317-330.	1.7	3
311	SCOT: Short Course Oncology Therapy—A comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, e14145-e14145.	0.8	3
312	Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer. <i>Value in Health</i> , 2022, 25, 230-237.	0.1	3
313	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , 0, 4, 108.	0.9	3
314	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, 28, 146-155.	0.5	3
315	PIN15 IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION: ESTIMATES FROM UNINFECTED AND INFECTED PERSONS IN THE UK. <i>Value in Health</i> , 2005, 8, A60.	0.1	2
316	Searching for a threshold — Not so. <i>Journal of Health Services Research and Policy</i> , 2007, 12, 190-191.	0.8	2
317	ISPOR-SMDM Task Force’s Recommendations for Good Modeling Practices—Reply to Letter to the Editor by Corro Ramos. <i>Value in Health</i> , 2013, 16, 1108.	0.1	2
318	A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for Depression After Psychosis: A Pilot Trial Protocol (ADAPT). <i>Psychosis</i> , 2016, 8, 143-155.	0.4	2
319	Enhancing the Value of the ASCO Value Framework. <i>MDM Policy and Practice</i> , 2018, 3, 238146831877622.	0.5	2
320	A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 775-784.	0.6	2
321	A criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1265-1298.	0.6	2
322	542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients. <i>Annals of Oncology</i> , 2020, 31, S473-S474.	0.6	2
323	Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 625-634.	1.0	2
324	Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: An expanded dataset.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3114-3114.	0.8	2

#	ARTICLE	IF	CITATIONS
325	Mendelian randomization: estimation of inpatient hospital costs attributable to obesity. <i>Health Economics Review</i> , 2021, 11, 16.	0.8	2
326	Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. <i>Clinical Colorectal Cancer</i> , 2021, 20, 236-244.	1.0	2
327	From Spreadsheets to Script: Experiences From Converting a Scottish Cardiovascular Disease Policy Model into R. <i>Applied Health Economics and Health Policy</i> , 2021, , 1.	1.0	2
328	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). <i>Trials</i> , 2022, 23, 307.	0.7	2
329	Unfinished Symphony: A Tribute to the Life and Career of Bernie Oâ€™Brien (1959â€“2004). <i>Medical Decision Making</i> , 2004, 24, 538-544.	1.2	1
330	PMH45 MAPPING UTILITY SCORES FROM THE EQ-5D AND SF-6D ONTO THE SCHIZOPHRENIA QUALITY OF LIFE SCALE. <i>Value in Health</i> , 2004, 7, 277.	0.1	1
331	Reply to â€œEvidence is still required for treatment as prevention for riskier routes of HIV transmissionâ€™. <i>Aids</i> , 2010, 24, 2892-2893.	1.0	1
332	Risk stratification for diabetic eye screening. Reply to Stratton I. M. and Aldington S. J. [letter]. <i>Diabetologia</i> , 2014, 57, 260-261.	2.9	1
333	Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. <i>BMJ Open</i> , 2017, 7, e014849.	0.8	1
334	Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials. <i>Pharmacoeconomics - Open</i> , 2020, 4, 649-655.	0.9	1
335	MO516A STRUCTURED EXPERT ELICITATION TO INFORM AND VALIDATE MORTALITY EXTRAPOLATIONS FOR A COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	1
336	Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study. <i>BMJ Open</i> , 2021, 11, e046912.	0.8	1
337	A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7101-7101.	0.8	1
338	A decision-analytic model of idelalisib in relapsed or refractory patients with indolent non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17655-e17655.	0.8	1
339	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 19-19.	0.8	1
340	Cost effectiveness of interferon in chronic active hepatitis C. <i>Medical Journal of Australia</i> , 1994, 161, 170-170.	0.8	1
341	Assessing the impact of restricted follow-up and small sample sizes on survival estimations in prostate cancer using registry data.. <i>Journal of Clinical Oncology</i> , 2016, 34, 294-294.	0.8	1
342	Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models. <i>Pharmacoeconomics</i> , 2022, 40, 257-268.	1.7	1

#	ARTICLE	IF	CITATIONS
343	Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study. <i>Oncology</i> , 2022, 100, 124-130.	0.9	1
344	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>MDM Policy and Practice</i> , 2022, 7, 238146832110610.	0.5	1
345	Interferon- α in Hepatitis C: The Authors'™ Reply. <i>Pharmacoeconomics</i> , 1997, 11, 491-492.	1.7	0
346	Empirical treatment or prompt endoscopy. <i>Lancet</i> , The, 2001, 357, 1366.	6.3	0
347	PMD21: AN INVESTIGATION OF PATIENT HETEROGENEITY AND THE POTENTIAL FOR BIAS IN MODELLING STUDIES:AN EXAMPLE USING A MARKOV MODEL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. <i>Value in Health</i> , 2003, 6, 299.	0.1	0
348	PRP23: ECONOMIC OUTCOMES OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH INHALED CORTICOSTEROIDS AND LONG-ACTING β -AGONISTS IN A HEALTH MAINTENANCE ORGANIZATION. <i>Value in Health</i> , 2003, 6, 373-374.	0.1	0
349	PCO3 ESTIMATING COST-EFFECTIVENESS OF INHALED CORTICOSTEROIDS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE PRESENCE OF MISSING DATA. <i>Value in Health</i> , 2004, 7, 256-257.	0.1	0
350	CV7 MODELLING SURVIVAL AND COSTS IN SWITZERLAND OF NESIRITIDE VERSUS INOTROPIC THERAPY FOR ACUTE DECOMPENSATED HEART FAILURE. <i>Value in Health</i> , 2004, 7, 642-643.	0.1	0
351	PR2 PERCEIVED UTILITY OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B: ESTIMATES FROM UNINFECTED PERSONS IN CANADA. <i>Value in Health</i> , 2005, 8, A18-A19.	0.1	0
352	PIN14 IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION: ESTIMATES FROM INFECTED AMERICANS. <i>Value in Health</i> , 2005, 8, A59-A60.	0.1	0
353	PGI18 META-ANALYSIS OF MULTIPLE TREATMENT COMPARISONS REPORTED AT MULTIPLE FOLLOW-UP TIMES. <i>Value in Health</i> , 2005, 8, A123-A124.	0.1	0
354	Joint Assessment of Intended and Unintended Effects of Medications: An Example Using Vascular Endothelial Growth Factor Inhibitors for Neovascular Age-Related Macular Degeneration. <i>Journal of Ophthalmology</i> , 2009, 2009, 1-9.	0.6	0
355	Health Economics in Asthma and COPD. , 2009, , 751-760.		0
356	Assessing the economic merits of managing cytomegalovirus infection in organ and stem cell transplantation. <i>Journal of Medical Economics</i> , 2009, 12, 68-76.	1.0	0
357	Statistical Issues with Trial Data and Economic Modeling for Cost-Effectiveness Evaluation. , 2012, , 149-166.		0
358	TCT-84 Fractional Flow Reserve versus Angiography in Guiding Management to Optimize Outcomes in Non-ST Elevation Myocardial Infarction (FAMOUS - NSTEMI) Clinical Trial: Study Design and Baseline Characteristics of Randomized Participants.. <i>Journal of the American College of Cardiology</i> , 2013, 62, B27.	1.2	0
359	TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM " CORRIGENDUM. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 112-112.	0.2	0
360	Rational allocation of resources available for healthcare: understanding cost effectiveness analyst. <i>Journal of the International AIDS Society</i> , 2014, 17, 19492.	1.2	0

#	ARTICLE	IF	CITATIONS
361	Assessment of the Health in Pregnancy Grant policy in Scotland: a natural experiment. <i>Lancet</i> , The, 2015, 386, S35.	6.3	0
362	Twenty-Five Years of Health Economics: A Tribute to Alan Maynard and Acknowledgement of the Work of the Editorial Board. <i>Health Economics (United Kingdom)</i> , 2017, 26, 3-5.	0.8	0
363	Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost. <i>Journal of the American College of Surgeons</i> , 2019, 229, e203-e204.	0.2	0
364	Cost-Effectiveness of Adjuvant Therapy for Stage IIIA Melanoma Is Poor Even When Patients Are Risk-Stratified by Gene Expression Profile. <i>Journal of the American College of Surgeons</i> , 2019, 229, e53.	0.2	0
365	The thorny issue of value alignment: how development-focused health technology assessment can help find win-win situations for patients and healthcare systems and commercial investors. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e57.	0.2	0
366	Economic and quality of life consequences of clinically important deterioration in patients with COPD: results from the TORCH study. , 2018, , .		0
367	Growth modulation index (GMI) as a comparative efficacy measure of larotrectinib versus prior systemic treatments for TRK fusion cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15638-e15638.	0.8	0
368	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, , 1-10.	0.5	0
369	Challenges for decision-makers when assessing within-class comparative effectiveness: the case of anticoagulation therapy for atrial fibrillation. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 131-138.	0.6	0
370	Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts. <i>Diabetes Therapy</i> , 2022, 13, 651-677.	1.2	0